Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats

A. Yamashita, Yoshikazu Yonemitsu, S. Okano, Kazunori Nakagawa, Y. Nakashima, T. Irisa, Y. Iwamoto, Y. Nagai, M. Hasegawa, K. Sueishi

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA), a systemic inflammatory disease of unknown etiology, mainly affects synovial joints. Although angiogenic growth factors, including fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), may play a critical role in the development and progression of RA joint disease, little information is now available regarding their exact role in initiation and/or progression of RA. In this study, we show that both polypeptides were up-regulated in the rat joint synovial tissue of an adjuvant-induced model of arthritis (AIA), as well as human subjects with RA. FGF-2 overexpression via Sendai virus-mediated gene transfer significantly worsened clinical symptoms and signs of rat AIA, including hind paw swelling and radiological bone destruction, as well as histological findings based on inflammatory reaction, synovial angiogenesis, pannus formation, and osteocartilaginous destruction, associated with up-regulation of endogenous VEGF. FGF-2 gene transfer to non-AIA joints was without effect. These findings suggested that FGF-2 modulated disease progression, but did not affect initiation. Reverse experiments using anti-FGF-2-neutralizin rabbit IgG attenuated clinical symptoms and histopathological abnormalities of AIA joints. To our knowledge, this is the first report indicating direct in vivo evidence of disease-modulatory effects of FGF-2 in AIA, as probably associated with endogenous VEGF function. FGF-2 may prove to be a possible therapeutic target to treat subjects with RA.

Original languageEnglish
Pages (from-to)450-457
Number of pages8
JournalJournal of Immunology
Volume168
Issue number1
DOIs
Publication statusPublished - Jan 1 2002

Fingerprint

Experimental Arthritis
Joint Diseases
Fibroblast Growth Factor 2
Rheumatoid Arthritis
Joints
Vascular Endothelial Growth Factor A
Sendai virus
Angiogenesis Inducing Agents
Genes
Signs and Symptoms
Arthritis
Disease Progression
Intercellular Signaling Peptides and Proteins
Up-Regulation
Immunoglobulin G
Rabbits
Bone and Bones
Peptides

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. / Yamashita, A.; Yonemitsu, Yoshikazu; Okano, S.; Nakagawa, Kazunori; Nakashima, Y.; Irisa, T.; Iwamoto, Y.; Nagai, Y.; Hasegawa, M.; Sueishi, K.

In: Journal of Immunology, Vol. 168, No. 1, 01.01.2002, p. 450-457.

Research output: Contribution to journalArticle

Yamashita, A, Yonemitsu, Y, Okano, S, Nakagawa, K, Nakashima, Y, Irisa, T, Iwamoto, Y, Nagai, Y, Hasegawa, M & Sueishi, K 2002, 'Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats', Journal of Immunology, vol. 168, no. 1, pp. 450-457. https://doi.org/10.4049/jimmunol.168.1.450
Yamashita, A. ; Yonemitsu, Yoshikazu ; Okano, S. ; Nakagawa, Kazunori ; Nakashima, Y. ; Irisa, T. ; Iwamoto, Y. ; Nagai, Y. ; Hasegawa, M. ; Sueishi, K. / Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. In: Journal of Immunology. 2002 ; Vol. 168, No. 1. pp. 450-457.
@article{1ce72b06a9114abdb7a468f297c75e59,
title = "Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats",
abstract = "Rheumatoid arthritis (RA), a systemic inflammatory disease of unknown etiology, mainly affects synovial joints. Although angiogenic growth factors, including fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), may play a critical role in the development and progression of RA joint disease, little information is now available regarding their exact role in initiation and/or progression of RA. In this study, we show that both polypeptides were up-regulated in the rat joint synovial tissue of an adjuvant-induced model of arthritis (AIA), as well as human subjects with RA. FGF-2 overexpression via Sendai virus-mediated gene transfer significantly worsened clinical symptoms and signs of rat AIA, including hind paw swelling and radiological bone destruction, as well as histological findings based on inflammatory reaction, synovial angiogenesis, pannus formation, and osteocartilaginous destruction, associated with up-regulation of endogenous VEGF. FGF-2 gene transfer to non-AIA joints was without effect. These findings suggested that FGF-2 modulated disease progression, but did not affect initiation. Reverse experiments using anti-FGF-2-neutralizin rabbit IgG attenuated clinical symptoms and histopathological abnormalities of AIA joints. To our knowledge, this is the first report indicating direct in vivo evidence of disease-modulatory effects of FGF-2 in AIA, as probably associated with endogenous VEGF function. FGF-2 may prove to be a possible therapeutic target to treat subjects with RA.",
author = "A. Yamashita and Yoshikazu Yonemitsu and S. Okano and Kazunori Nakagawa and Y. Nakashima and T. Irisa and Y. Iwamoto and Y. Nagai and M. Hasegawa and K. Sueishi",
year = "2002",
month = "1",
day = "1",
doi = "10.4049/jimmunol.168.1.450",
language = "English",
volume = "168",
pages = "450--457",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats

AU - Yamashita, A.

AU - Yonemitsu, Yoshikazu

AU - Okano, S.

AU - Nakagawa, Kazunori

AU - Nakashima, Y.

AU - Irisa, T.

AU - Iwamoto, Y.

AU - Nagai, Y.

AU - Hasegawa, M.

AU - Sueishi, K.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Rheumatoid arthritis (RA), a systemic inflammatory disease of unknown etiology, mainly affects synovial joints. Although angiogenic growth factors, including fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), may play a critical role in the development and progression of RA joint disease, little information is now available regarding their exact role in initiation and/or progression of RA. In this study, we show that both polypeptides were up-regulated in the rat joint synovial tissue of an adjuvant-induced model of arthritis (AIA), as well as human subjects with RA. FGF-2 overexpression via Sendai virus-mediated gene transfer significantly worsened clinical symptoms and signs of rat AIA, including hind paw swelling and radiological bone destruction, as well as histological findings based on inflammatory reaction, synovial angiogenesis, pannus formation, and osteocartilaginous destruction, associated with up-regulation of endogenous VEGF. FGF-2 gene transfer to non-AIA joints was without effect. These findings suggested that FGF-2 modulated disease progression, but did not affect initiation. Reverse experiments using anti-FGF-2-neutralizin rabbit IgG attenuated clinical symptoms and histopathological abnormalities of AIA joints. To our knowledge, this is the first report indicating direct in vivo evidence of disease-modulatory effects of FGF-2 in AIA, as probably associated with endogenous VEGF function. FGF-2 may prove to be a possible therapeutic target to treat subjects with RA.

AB - Rheumatoid arthritis (RA), a systemic inflammatory disease of unknown etiology, mainly affects synovial joints. Although angiogenic growth factors, including fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF), may play a critical role in the development and progression of RA joint disease, little information is now available regarding their exact role in initiation and/or progression of RA. In this study, we show that both polypeptides were up-regulated in the rat joint synovial tissue of an adjuvant-induced model of arthritis (AIA), as well as human subjects with RA. FGF-2 overexpression via Sendai virus-mediated gene transfer significantly worsened clinical symptoms and signs of rat AIA, including hind paw swelling and radiological bone destruction, as well as histological findings based on inflammatory reaction, synovial angiogenesis, pannus formation, and osteocartilaginous destruction, associated with up-regulation of endogenous VEGF. FGF-2 gene transfer to non-AIA joints was without effect. These findings suggested that FGF-2 modulated disease progression, but did not affect initiation. Reverse experiments using anti-FGF-2-neutralizin rabbit IgG attenuated clinical symptoms and histopathological abnormalities of AIA joints. To our knowledge, this is the first report indicating direct in vivo evidence of disease-modulatory effects of FGF-2 in AIA, as probably associated with endogenous VEGF function. FGF-2 may prove to be a possible therapeutic target to treat subjects with RA.

UR - http://www.scopus.com/inward/record.url?scp=0036135611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036135611&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.168.1.450

DO - 10.4049/jimmunol.168.1.450

M3 - Article

C2 - 11751992

AN - SCOPUS:0036135611

VL - 168

SP - 450

EP - 457

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -